Nonverbal Communication in Dementia Care: A Review of Its Application and Influence on Patients’ Quality of Life

2025-12-15T15:49:12+08:00

Objective: To review the mechanism, application scenarios, and existing problems of nonverbal communication in improving dementia patients’ quality of life and to provide a reference for nursing practice and future research. Methods: Literature related to “dementia”, “non-verbal communication”, and “quality of life” published from 202 to 2024 was searched through CNKI, Wanfang, PubMed, etc., are included in studies on clinical nursing, non-pharmacological interventions, and communication strategies for narrative integration. Results: Existing studies show that nonverbal communication elements (eyes, gestures, touch, spatial distance, intonation, and environmental cues) can improve patients’ subjective security and quality of life through cognitive activation, emotion regulation, memory arousal, behavioral stability, self-care promotion, and social participation. Application needs and implementation priorities differ across hospitals, elderly care institutions, and home care. Current evidence is limited by small sample sizes, high heterogeneity, and a lack of standardized assessment tools and high-quality randomized controlled trials. Conclusion: Nonverbal communication is a key nursing strategy to compensate for language barriers and improve quality of life in dementia care. In the future, it is necessary to establish a unified evaluation system, conduct high-quality multi-center research, and explore AI’s potential to support objective quantification and individualized intervention of nonverbal signals.

Firsekibart in Reducing High-Sensitivity C-reactive Protein Levels of Gout

2025-11-26T11:50:31+08:00

Background: Gout remains a challenging condition with rising global prevalence. The IL-1β drives disease pathogenesis, and high-sensitivity C-reactive protein (hsCRP) correlates with gout activity. Firsekibart, a novel fully human anti-IL-1β monoclonal antibody, has proven its efficacy on gout, while the data on reducing hsCRP remains limited. Methods: This multicenter, randomized, double-blind phase III trial compared Firsekibart (200 mg subcutaneous) with compound betamethasone (7 mg intramuscular) in acute gout patients who were contraindicated to, intolerant of, or unresponsive to NSAIDs and/or colchicine. Serum hsCRP levels were measured at 72 hours, 7 days post-dose, and 4 weeks post-dose. Results: Both groups achieved comparable hsCRP reduction at 72 hours (Firsekibart: −14.68 mg/L [95% CI: −15.75, −13.61] vs. compound betamethasone: −14.58 mg/L [−15.66, −13.50]; P=0.898). Firsekibart demonstrated better sustained suppression at 7 days post-dose (−18.63 vs. −9.28 mg/L, P<0.001) and 4 weeks (−18.37 vs. −12.65 mg/L, P<0.0001). Conclusion: Compared with compound betamethasone, Firsekibart showed a longer-lasting anti-inflammatory effect on gout patients. This result may provide significant clinical value in the management of gout and its associated complications.

International Journal of General Practice Nursing

Nonverbal Communication in Dementia Care: A Review of Its Application and Influence on Patients’ Quality of Life

Firsekibart in Reducing High-Sensitivity C-reactive Protein Levels of Gout